wegovy vs tirzepatide weight loss Semaglutide Tirzepatide: Head-to-Head for & Diabetes Semaglutide vs Tirzepatide: Which Works

Unexplained weight loss deserves evaluation before assuming it is beneficial

We remain informed about market changes to provide the best advice to our patients

This is a genuinely novel clinical phenomenon

Insurance companies usually dont cover tirzepatide for weight loss because obesity is still considered a cosmetic issue as opposed to a chronic disease

Molecular Identity Developer Innovent Biologics (China) / Eli Lilly partnership Mechanism Dual GLP-1 and glucagon receptor agonist GIP Activation No Administration Weekly subcutaneous Development Stage Phase 3 trials (primarily in China) Glucagon Receptor Pathway The glucagon receptor activation in Mazdutide engages metabolic pathways distinct from GIP: Hepatic metabolism: Glucagon signaling activates liver-based energy expenditure pathways Thermogenesis: Documented effects on energy expenditure in preclinical models Lipid metabolism: Research indicates effects on liver lipid processing Different satiety mechanism: Complementary to GLP-1's central appetite effects Published Research Mazdutide clinical data has been published primarily from Chinese trial populations: Trial Phase Population Key Findings GLORY-1 Phase 3 Chinese adults Metabolic endpoints documented GLORY-2 Phase 3 Chinese adults Glycemic pathway effects documented IBI362 Phase 2 Phase 2 Multiple cohorts Dose-response relationships established Tirzepatide: GLP-1 + GIP Tirzepatide represents the most established dual-agonist compound with full FDA approval and extensive published literature

Note that the semaglutide dose in SURPASS-2 was 1 mg (not the 2 mg diabetes dose or 2.4 mg obesity dose), so these comparisons don't represent maximal semaglutide